Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | XmAb541 + XmAb808 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| XmAb541 | XmAb-541|XmAb 541 | CD3 Antibody 125 CLDN6 Antibody 10 | XmAb541 is a bispecific antibody targeting CLDN6 and CD3 that redirects cytotoxic T-lymphocytes towards tumor cells expressing CLDN6, potentially resulting in increased tumor cell killing (J Clin Oncol 2025 43: 5_suppl, TPS652, NCI Drug Dictionary). | |
| XmAb808 | XmAb-808|XmAb 808 | CD276 Antibody 24 CD28 Antibody 14 | XmAb808 is a bispecific antibody that targets CD276 (B7-H3) on tumor cells and CD28 expressed on T-lymphocytes, which potentially leads to enhanced antitumor immune response (Journal for ImmunoTherapy of Cancer 2023;11). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07593092 | Phase I | XmAb541 + XmAb808 | Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors | Not yet recruiting | USA | 0 |